Turkmenistan Medical Device Registration: Free Sale Certificate and Foreign Market Evidence

1. Key takeaways

In the Turkmenistan registration documentation, the proof that a product is already lawfully marketed elsewhere is a set of documents that complement one another, rather than a single certificate:

• Certificate of Free Sale (CFS);
• Registration certificate of the country of manufacture (country of origin);
• Other documents (registration certificates) issued by the regulatory authorities of other countries responsible for placing products on the market or circulating them;
• Any other certificate capable of showing that the product is used in other countries and meets effectiveness and safety requirements.

The practical conclusion is: submit everything obtainable, and make sure the information across the documents is mutually consistent. The set works as layered evidence. A certificate from one authority corroborates the others, and together they build the picture of an established, supervised product that the Turkmen reviewers are looking for. Gaps in the set are not necessarily fatal, but contradictions inside the set almost always are, because a discrepancy between two official documents shifts the burden of explanation onto the applicant.

2. Legal basis

Law No. 319-V of January 12, 2016 establishes the general documentation duty for national registration, and the Regulation on National Registration of Medicines and Medical Devices approved by the Ministry of Health contains the operative list under which the free sale certificate and foreign registration certificates are filed. The list item is framed broadly, which is what allows the layered approach described below: the regulation names categories of evidence rather than a single mandatory document.

3. Expert insights

Insight 1: this set of documents answers the question of whether the product is lawful and safe in other countries.

The document list places these items in the category of documents certifying that the device complies with the requirements of technical specifications or standards, and states their role as showing that the product is used in other countries and meets effectiveness and safety requirements. This is the classic indirect evidence route. Turkmenistan has no reliance mechanism, but it obtains reference information through these documents. In other words, foreign approvals do not substitute for the national procedure, yet they carry persuasive weight inside it, and the stronger and more consistent the foreign evidence, the smoother the review tends to be.

Insight 2: the free sale certificate and the registration certificate are related as or, not as and.

The wording of the list is a free sale certificate; other documents (registration certificates) issued by the authority regulating the circulation of medical devices. The two are alternatives or may be filed together. In practice, however, filing both is the safer course: the CFS proves that the product can be freely sold, while the registration certificate proves that it has undergone technical review, and the two carry their probative force in different directions. A reviewer who sees both has fewer open questions, and an applicant who files only one should expect the other to be requested during the completeness check.

Insight 3: these documents must be submitted as originals or legalized copies, with Russian translations attached.

The regulatory wording is explicit: the CPP and/or registration certificates of the country of manufacture and of other countries must be submitted in the form of originals or legalized copies, and Russian translations must be attached. This connects directly to the consular legalization chain of article 15, and the CFS together with the registration certificates are the two heaviest documents in the chain. Planning their issue dates, legalization slots and translation batches together is the efficient way to keep this workstream from becoming the project bottleneck.

Insight 4: consistency of information matters more than the number of documents.

The product name, model, manufacturer name and manufacturer address on the CFS must be fully identical with those in the application form, the country-of-origin registration certificate, the ISO 13485 certificate and the instructions for use. A single inconsistency will trigger a request for explanation or for corrective documents. Article 22 explains the level of granularity at which the manufacturing company name and address should be stated. Consistency checking is cheap when done internally before submission and expensive when done by the reviewer after it.

Insight 5: the mistake Chinese companies most often make is submitting only the NMPA registration certificate.

An NMPA registration certificate proves lawful marketing in China only; the CFS is what proves that the product can be freely sold. The two carry different probative force, and both should be prepared: the NMPA registration certificate plus a CFS issued by the competent Chinese authority or its authorized body. Chinese exporters should also note that CFS issuing practice and lead times differ across issuing bodies, so the certificate request should be placed as early as the project schedule allows.

4. Practical recommendations

1. Prepare both the CFS and the country-of-origin registration certificate, and do not choose one over the other.
2. Check the five consistency points one by one: product name, model, manufacturer name, address, validity period.
3. Prepare the documents as originals or legalized copies and complete consular legalization.
4. Attach Russian translations, produced by a translator with a medical background.
5. Consolidate the marketing evidence from all countries into a single cross-reference table, which makes it easy for reviewers to locate documents.

5. Verification checklist

• □ Both the CFS and the country-of-origin registration certificate have been obtained (filed together).
• □ The five consistency points have been checked (name, model, manufacturer name, address, validity period).
• □ The documents have been prepared as originals or legalized copies and authenticated.
• □ The Russian translations have been attached and professionally reviewed.
• □ A cross-reference table of marketing evidence from all countries has been compiled.

Regulatory information verified as of October 30, 2026. The content of this document was checked against Law No. 319-V on the Supply of Medicines (January 12, 2016) and the Regulation on National Registration of Medicines and Medical Devices approved by the Ministry of Health (the list of documents certifying compliance with technical specifications or standards, including the free sale certificate and registration certificates of other countries); the requirement that documents be submitted as originals or legalized copies with Russian translations attached is applied in accordance with the current Regulation.

• Local resources in Turkmenistan: GRZAN can coordinate licensed local import entities and authorized representative resources, covering national registration submission, the consular legalization chain for documents, sample delivery, interfaces with mandatory TDS certification, and customs clearance support.
• Service scope: classification determination, selection of the registration pathway, preparation of national-format dossiers, consular legalization and notarization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, changes and renewal, vigilance and post-market maintenance.
• Contact: GRZAN supports manufacturers, importers and authorized representatives with registration in this country; reach us at info@grzanglobal.com.